Leflunomide Market is projected to grow from USD 634.2 Million in 2024 to USD 1.12 Billion by 2032, at a 7.3% CAGR. Growth is driven by rising rheumatoid arthritis prevalence, increasing demand for cost-effective treatments, aging populations, improved diagnostic capabilities, and expanding availability of generic formulations.
Full Report
https://www.24chemicalresearch.....com/reports/266762/